An international atherosclerosis society position paper: Global recommendations for the management of dyslipidemia

Research output: Contribution to journalArticle

80 Scopus citations


An international panel of the International Atherosclerosis Society has developed a new set of recommendations for management of dyslipidemia. The panel identifies non-high density lipoprotein cholesterol (non-HDL-C) as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for higher risk subjects. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.

Original languageEnglish (US)
Pages (from-to)561-565
Number of pages5
JournalJournal of Clinical Lipidology
Issue number6
Publication statusPublished - Nov 2013



  • Atherosclerosis
  • Cardiovascular risk
  • Cholesterol
  • Lifestyle therapies
  • Lipoproteins
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Nutrition and Dietetics

Cite this